Ionis Pharmaceuticals (NASDAQ:IONS) reported Q2 2025 GAAP revenue and non-GAAP earnings per share that exceeded analyst expectations by wide margins. The profit surge in Q2 2025 included a ...

The Oligonucleotide Therapeutics Society (OTS) is pleased to announce the 21st Annual OTS Meeting, scheduled for October ...

Gene therapy appears to be a promising approach for a subset of genetic deafness, although challenges remain with development ...

Fintel reports that on July 31, 2025, Morgan Stanley upgraded their outlook for Ionis Pharmaceuticals (NasdaqGS:IONS) from ...